Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorAstraZeneca
About this trial
The objectives of this study are to describe the incidence of adverse events and the effectiveness of tezepelumab in patients receiving tezepelumab as indicated for severe asthma or CRSwNP in South Korea.
Eligibility criteria
Qualifiers
Patients who are treated with at least one dose of tezepelumab according to the indication in the locally approved prescribing information
Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
Disqualifiers
Other off-label indications according to the locally approved prescribing information
Current participation in any interventional trial
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov